Azelis After a 59% Drop: The Business That Kept Printing Cash While the Stock Fell Apart

Azelis's stock is down nearly 60% over the past year. Kepler Cheuvreux downgraded it. Analysts cut their price targets. The narrative — organic revenue decline, rising leverage, geopolitical disruption — felt like it had legs.

Then came Q2 2026. After four straight quarters of organic decline, Azelis posted 3.9% organic growth. Gross margins expanded. EBITA margins widened to 11.4% in the quarter, the best reading in two years. All three regions grew.

The stock has not rallied. It trades around €11.50, well below where it sat a year ago. The market is still pricing the old risk profile while the operating setup is already getting cleaner. The gap between tape pain and business pain is where this story lives.

The old story, and why it was reasonable

Azelis is Belgium's specialty chemicals and food ingredients distributor — €4.1 billion in annual revenue, 4,200 employees, operations in 65 countries. It does not make the chemicals; it moves them, formulates them, and sells them to pharma, personal care, coatings, agriculture, and food companies worldwide. The business is asset-light and diversified, and the model works: buy specialty products, add technical service, sell at a margin.

Through most of 2025, the story turned against it. Organic revenue contracted 1.6% in constant currency for the full year. Adjusted EBITDA fell 10%, and the leverage ratio drifted up from 2.9x to 3.3x as net debt held near €1.6 billion. The Middle East conflict disrupted supply chains. Tariff uncertainty hit Asia Pacific. End markets softened. Kepler Cheuvreux downgraded Azelis from Buy to Hold in August 2025, cutting its price target from €19 to €14, then lower again, citing balance sheet concerns and limited M&A capacity at current leverage levels. The stock kept falling. By early 2026 it was down 40% from its 2024 levels. By mid-2026, the decline had reached roughly 59%.

At that point the narrative had hardened: declining sales, stuck leverage, and no end in sight for the geopolitical disruption.

The cash flow that nobody expected

Here is the number that makes the story stale: Azelis generated €442 million in free cash flow for the full year 2025. That was a 29% increase over 2024's €342 million, achieved while EBITDA fell 10%. The free cash flow conversion ratio hit 106% — the second-highest on record for the company.

This is not about excitement. It is about a business that looks harder to dismiss once the free cash flow shows up.

The mechanics are straightforward. Azelis improved working capital management — reducing days inventory outstanding from 57 to 51 days and bringing net working capital as a share of revenue down from 15.9% to 14.1%. Cost savings from a structural program came in above the €20 million annualized target. Gross profit held at €968 million despite the revenue decline. The company collected cash faster than it spent it.

If you are trying to value a beaten-down business, this is the bridge. Not a DCF model — those are the illusion of control — but the simple arithmetic of cash coming in, debt staying flat, and earnings per share rising 5.5% in constant currency to €0.52 for the first half of 2026.

What changed in Q2

The quarterly trend is the one proof point that can make the updated case financially concrete.

Azelis reported Q1 2026 with a 3.9% organic revenue decline, consistent with the pattern that had pushed the stock lower. Then Q2 reversed the trajectory entirely:

• Organic revenue growth of 3.9% year-over-year
• Revenue of €1.1 billion, up 6.3% in constant currency
• Gross margin expanded 96 basis points to 24.7%
• Adjusted EBITA margin expanded 66 basis points to 11.4%

Asia Pacific grew 12.7% organically. Americas returned to 5.9% organic growth after months of weakness. EMEA, the weakest region for two quarters, grew 4.9% in the quarter. Pricing momentum turned positive across multiple end markets after months of deflation.

This is not a one-off. The H1 2026 results showed the full half year at 0.3% organic growth on €2.2 billion in revenue. Not dramatic, but the inflection from contraction to expansion matters when the market has been pricing continued decline.

The valuation gap

Azelis trades at roughly 10.8 times its last-twelve-month EV/EBITDA. The company's five-year average on that metric was 16.7x. That is not a trivial discount — it is a full multiple compression.

On a forward basis, analysts estimate full-year 2026 cash EPS around €1.00 to €1.10, which would put the stock at a forward multiple of roughly 10 to 11 times. For a business generating €442 million in free cash flow on €4.1 billion in revenue, that is a multiple consistent with permanent deterioration, not a company that just returned to organic growth with expanding margins.

The EV/EBITDA discount to the five-year average is what a rerating would mean in concrete terms. If Azelis trades back to even the lower end of its historical range — 14x instead of 10.8x — the enterprise value moves from roughly €4.6 billion to €6 billion. That is the math the market has not priced in.

The consensus price target sits around €13.20, up roughly 15% from current levels. But that target reflects incremental optimism, not a full recognition of what happens if the multiple recovers toward its own history.

The balance sheet that still worries people

This is where the bear argument still has weight, and it should.

Net debt is €1.6 billion. The leverage ratio is 3.4x, above the company's target range of 2.5x to 3.0x. Fitch rates Azelis BB+ with a stable outlook, which is solid but not investment grade. Leverage of this level limits M&A flexibility — you cannot keep buying your way to growth when the balance sheet is already extended. And the 3.4x ratio in H1 2026 is slightly higher than it was at year-end 2025, because working capital requirements rose with the stronger Q2 performance.

The bear's claim is simple: €1.6 billion of debt on a business generating €400-500 million in EBITDA is not a trivial burden, and a downturn would stress it further. Kepler flagged this explicitly. The leverage concern is real.

The counter is also simple: €442 million in free cash flow against €1.6 billion in net debt means the business can pay down the entire debt load in roughly 3.6 years at current cash generation. That is not a fast deleveraging pace, but it is not a crisis either. The leverage ratio improved from a peak of 3.4x in September 2025 to 3.3x by year-end, and the company generated enough cash in Q1 2026 alone to reduce net debt to €1.5 billion. Cash generation is the deleveraging engine, and it has been working even when earnings did not.

What would prove the thesis wrong

If Q3 and Q4 2026 return to organic decline, the inflection story collapses and the 10.8x multiple may be exactly right. The Q2 turnaround needs to hold — not one quarter of surprise, but a sustained return to positive organic growth across the second half.

If geopolitical disruption escalates and working capital balloons again, free cash flow could swing sharply lower. Azelis's FCF conversion ratio dropped from 106% in FY2025 to 52% in H1 2026, primarily because of higher working capital tied to stronger Q2 performance. The ratio can go either way.

If gross margins stop expanding or contract again, the pricing momentum that turned positive in Q2 was a temporary blip, not a trend.

The break condition is straightforward: if organic revenue declines again and margins do not hold, the operating path has not improved and the multiple deserves its discount. Watch the Q3 numbers. They report in October.

Where we are

Azelis is a €2.9 billion company generating €442 million in annual free cash flow, trading at a multiple nearly 35% below its five-year average, after a 59% stock decline that was driven by a period of organic contraction that appears to have ended. The leverage is elevated but manageable, the credit rating is stable, and the cash flow engine is intact.

The market is pricing a business that continues to struggle. The numbers suggest a business that turned the corner and has been generating cash through the entire cycle. Whether the next two quarters confirm the reversal or reverse it is what separates this from a simple beaten-down-stock recap.

The setup is not about excitement. It is about a business that may soon look a lot harder to dismiss once the next two quarters land where Q2 pointed.